Clinical and basic research on BCMA-CAR T cells in the treatment of multiple myeloma

Conditions

Multiple Myeloma

Shuyang Wang, Qian Wu, Mengmeng Huang, Mingming Zhang, Shan Fu et al. (12 authors)

Blood2025-11-03

10.1182/blood-2025-2381

Clinical Characteristics and Outcomes of BCMA-Targeted CAR-T Cell Recipients with Coronavirus Disease 2019 during the Omicron Wave: A Retrospective Study

Haiqiong Zheng, Han Shi, Houli Zhao, Yongxian Hu, He Huang

Blood2024-11-05

10.1182/blood-2024-207233

Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapy.

Wang L, Hong R, Zhou L, Wang Y, Lv Y, Ni F, Zhang M, Zhao H, Ding S, Chang AH, Xu H, Hu Y, Wei G, Huang H.

2022-12-075 citations

10.1016/j.jcyt.2022.11.001

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies.

Hu Y, Li J, Ni F, Yang Z, Gui X, Bao Z, Zhao H, Wei G, Wang Y, Zhang M, Hong R, Wang L, Wu W, Mohty M, Nagler A, Chang AH, van den Brink MRM, Li MD, Huang H.

2022-09-09100 citations

10.1038/s41467-022-32960-3

Clinical features of hemophagocytic syndrome following BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.

Zu C, Wang K, Zhang Q, Hu Y, Huang H.

2022-04-0111 citations

10.3724/zdxbyxb-2022-0039

Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission

Yiyun Wang, Linqin Wang, Yifan Zeng, Ruimin Hong, Cheng Zu et al. (12 authors)

Frontiers in Oncology2021-11-179 citations

10.3389/fonc.2021.755584

Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy

Mingming Zhang, Linghui Zhou, Houli Zhao, Yanlei Zhang, Guoqing Wei et al. (16 authors)

Clinical Cancer Research2021-09-2141 citations

10.1158/1078-0432.ccr-21-2031

Shao M, Yu Q, Teng X, Guo X, Wei G, Xu H, Cui J, Chang AH, Hu Y, Huang H.

2021-02-1921 citations

10.1038/s41409-021-01226-9

Potent Anti-Tumor Activity of Bcma CAR-T Therapy Against Heavily Treated Multiple Myeloma and Dynamics of Immune Cell Subsets Using Single-Cell Mass Cytometry

Yongxian Hu, Yanlei Zhang, Guoqing Wei, Chang alex Hong, He Huang

Blood2019-11-1317 citations

10.1182/blood-2019-130341

Interventions

Case series:BCMA-CART therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Relasped or refractory hematological malignancies with BCMA positive; 2. Expected life time is more than 12 weeks; 3. urine pregnancy test negative; 4. Voluntarily participate in the trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. patients with the history of epilepsy or other CNS disease; 2. patiets with GVHD who need immunosuppressive agents; 3. Patients with prolonged QT interval time or severe heart disease; 4. Patients with active hepatitis B or C infection; 5. patients with HIV infection.

Design outcomes

Primary

Measure	Time frame
the response of CART;overall survival;disease-free survival;recurrence rate;CRS rate;	—

Countries

China

Contacts

Public ContactHuang He

the First Affiliated Hospital of Zhejiang University School of Medicine

hehuangyu@126.com+86 13605714822

Outcome results

None listed